Peptilogics, Inc.

Peptilogics is an early clinical stage company dedicated to developing innovative peptide therapeutics. These therapies that have not yet been approved by FDA may or may not be effective as a treatment, and might cause unexpected serious side effects.

We encourage patients to participate in clinical trials, which offer the best opportunity for access to an investigational product before regulatory approval.

In rare cases, where a patient does not meet the requirements for participation in a clinical study, the FDA may grant permission, upon request by a treating physician, for a pharmaceutical manufacturer to provide an unapproved therapy to the treating physician for a qualifying patient through a process called expanded access. At this time, participation in clinical trials is the only way for patients to gain access to investigational therapies under development by Peptilogics.

Peptilogics encourages patients to speak with their physicians about possible clinical trial participation. Information about our investigational therapies and ongoing clinical trials can be found on www.clinicaltrials.gov.